← Back to Calendar
Live Company Data
NCM
Updated
just now
· Data: FMP
Current Price
$2.32
-90.34%
$-21.70 today
Day: $2.18 – $2.33
Market Cap
N/A
Shares out: 5.34M
Float: 5.29M
52-Week Range
Current price is at 2% of 52-week range
Sector
Healthcare
Biotechnology
⚠️ Financial data is for informational purposes only. Not investment advice. Prices may be delayed.
Indication
Relapsed/refractory AML — MIRACLE Phase 2B/3 interim readout
Key Notes
MIRACLE Phase 2B/3 trial interim readout expected mid-2026 (unblinding triggered after 45 subjects enrolled). 45th subject enrolled March 23, 2026 — interim now imminent. Annamycin is designed to overcome multidrug resistance in AML; AnnAraC = annamycin + cytarabine combination. Trial enrolling relapsed/refractory AML patients; primary endpoint: overall response rate. Sub-$100M market cap — positive interim data could be significant catalyst. Date is approximate (mid-2026).
⚠️ Not Investment Advice: This information is provided for educational purposes only.
PDUFA dates are FDA target action dates, not guaranteed approval dates. The FDA may extend the review period,
issue Complete Response Letters, or take unexpected actions. Probability of approval scores are based on
historical base rates and do not account for drug-specific factors. Always consult a financial advisor
before making investment decisions.
Discussion
Share your analysis, research, or questions about this catalyst. No account required.